JP2013508454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508454A5 JP2013508454A5 JP2012536876A JP2012536876A JP2013508454A5 JP 2013508454 A5 JP2013508454 A5 JP 2013508454A5 JP 2012536876 A JP2012536876 A JP 2012536876A JP 2012536876 A JP2012536876 A JP 2012536876A JP 2013508454 A5 JP2013508454 A5 JP 2013508454A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pharmaceutically acceptable
- adrenergic receptor
- receptor agonist
- erythema
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010015150 Erythema Diseases 0.000 claims 22
- 230000001154 acute effect Effects 0.000 claims 21
- 231100000321 erythema Toxicity 0.000 claims 21
- 238000011282 treatment Methods 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 14
- 239000000126 substance Substances 0.000 claims 9
- 239000000695 adrenergic alpha-agonist Substances 0.000 claims 7
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 5
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 5
- 229960003679 brimonidine Drugs 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims 2
- 229960001528 oxymetazoline Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 claims 1
- GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 238000005299 abrasion Methods 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 238000004299 exfoliation Methods 0.000 claims 1
- 229960005016 naphazoline Drugs 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229960001802 phenylephrine Drugs 0.000 claims 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- -1 tetrahydrozaline Chemical compound 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960000833 xylometazoline Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25480509P | 2009-10-26 | 2009-10-26 | |
| US61/254,805 | 2009-10-26 | ||
| PCT/US2010/053198 WO2011053487A1 (en) | 2009-10-26 | 2010-10-19 | Methods of treating or preventing acute erythema |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508454A JP2013508454A (ja) | 2013-03-07 |
| JP2013508454A5 true JP2013508454A5 (enExample) | 2013-12-26 |
Family
ID=43922456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012536876A Pending JP2013508454A (ja) | 2009-10-26 | 2010-10-19 | 急性紅斑の治療又は予防法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110224216A1 (enExample) |
| EP (1) | EP2493309A4 (enExample) |
| JP (1) | JP2013508454A (enExample) |
| KR (1) | KR20120125230A (enExample) |
| CN (1) | CN102711471A (enExample) |
| AU (1) | AU2010313643B2 (enExample) |
| BR (1) | BR112012009891A2 (enExample) |
| CA (1) | CA2779063A1 (enExample) |
| MX (1) | MX2012004890A (enExample) |
| NZ (1) | NZ600125A (enExample) |
| RU (1) | RU2012122983A (enExample) |
| WO (1) | WO2011053487A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20110172180A1 (en) | 2010-01-13 | 2011-07-14 | Allergan Industrie. Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| AU2011231543B2 (en) | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
| JP5747392B2 (ja) | 2010-03-26 | 2015-07-15 | ガルデルマ・リサーチ・アンド・デヴェロップメント | 毛細血管拡張症の安全かつ有効な治療のための改善された方法および組成物 |
| US8911713B2 (en) | 2010-06-30 | 2014-12-16 | Galderma Research & Development | Method for preventing or treating skin tumor |
| EP2595616B1 (en) | 2010-06-30 | 2016-04-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
| DK2444068T4 (en) | 2010-10-21 | 2018-03-05 | Galderma Sa | Brimonide sub-composition |
| ES2742273T3 (es) | 2011-02-15 | 2020-02-13 | Aclaris Therapeutics Inc | Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea |
| UA109359C2 (xx) * | 2011-11-10 | 2015-08-10 | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| US9283217B2 (en) | 2011-11-10 | 2016-03-15 | Allergan, Inc. | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| CA2911472A1 (en) * | 2013-05-06 | 2014-11-13 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| ES2671734T3 (es) * | 2014-06-30 | 2018-06-08 | Galderma S.A. | Procedimiento de tratamiento de los sofocos asociados con tumores carcinoides y síndrome carcinoide |
| CN106361733A (zh) * | 2015-07-22 | 2017-02-01 | 刘里远 | 外用经穴激动剂 |
| EP3434271B1 (en) | 2016-03-22 | 2020-08-26 | Doris Maria Hexsel | Use of pharmaceutical composition for the treatment of poikiloderma of civatte |
| FR3119986B1 (fr) | 2021-02-19 | 2024-02-16 | Tarian Pharma | Composition émulsion eau dans huile et ses utilisations dans la prévention et/ou le traitement des dommages cutanés causés par les rayonnements |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6911196B2 (en) * | 2002-07-31 | 2005-06-28 | Samir I. Hamtini | Topical medicament for treating nappy rash |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US8410102B2 (en) * | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
| US20050020600A1 (en) * | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| US20050226899A1 (en) * | 2004-04-08 | 2005-10-13 | Mauro Castiglioni | Cosmetic mask composition |
| DK1761266T3 (da) * | 2004-05-25 | 2013-08-05 | Galderma Pharma Sa | Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme |
| US7709014B2 (en) * | 2005-10-17 | 2010-05-04 | Yu Ruey J | Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites |
| US20090061020A1 (en) * | 2007-08-31 | 2009-03-05 | Theobald Klaus P | Brimonidine Compositions for Treating Erythema |
| AU2011231543B2 (en) * | 2010-03-26 | 2015-01-15 | Galderma Research & Development | Improved methods and compositions for safe and effective treatment of erythema |
| US20120101104A1 (en) * | 2010-10-21 | 2012-04-26 | Galderma S.A. | Topical gel compositions and methods of use |
| US8053427B1 (en) * | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
-
2010
- 2010-10-19 CA CA2779063A patent/CA2779063A1/en not_active Abandoned
- 2010-10-19 BR BR112012009891A patent/BR112012009891A2/pt active Search and Examination
- 2010-10-19 JP JP2012536876A patent/JP2013508454A/ja active Pending
- 2010-10-19 NZ NZ60012510A patent/NZ600125A/en not_active IP Right Cessation
- 2010-10-19 AU AU2010313643A patent/AU2010313643B2/en not_active Ceased
- 2010-10-19 WO PCT/US2010/053198 patent/WO2011053487A1/en not_active Ceased
- 2010-10-19 MX MX2012004890A patent/MX2012004890A/es unknown
- 2010-10-19 KR KR1020127013737A patent/KR20120125230A/ko not_active Ceased
- 2010-10-19 CN CN2010800485638A patent/CN102711471A/zh active Pending
- 2010-10-19 EP EP20100827329 patent/EP2493309A4/en not_active Withdrawn
- 2010-10-19 US US12/907,543 patent/US20110224216A1/en not_active Abandoned
- 2010-10-19 RU RU2012122983/15A patent/RU2012122983A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508454A5 (enExample) | ||
| RU2012122983A (ru) | Способ лечения и профилактики острой эритемы | |
| Ibbotson et al. | Ambulatory photodynamic therapy using low irradiance inorganic light‐emitting diodes for the treatment of non‐melanoma skin cancer: an open study | |
| Andreu et al. | Current progress and challenges of nanoparticle-based therapeutics in pain management | |
| CA2780586C (en) | Combination therapy for treating or preventing an inflammatory skin disorder | |
| US20120076738A1 (en) | Combination treatment for dermatological conditions | |
| Ma et al. | Prospective study of topical 5‐aminolevulinic acid photodynamic therapy for the treatment of severe adolescent acne in Chinese patients | |
| WO2009053741A3 (en) | Novel formulation | |
| ECSP099348A (es) | Composición farmacéutica de liberación modificada de un músculo relajante y un aine | |
| JP2014530847A5 (enExample) | ||
| Holliday et al. | Methotrexate: role of treatment in skin disease | |
| RU2014119919A (ru) | Способ лечения капиллярных гемангиом | |
| AU2016216627A1 (en) | Pharmaceutical compositions comprising 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| Nilforoushzadeh et al. | A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. | |
| US20160151349A1 (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| US20110294894A1 (en) | Pharmaceutical Composition for the Treatment of Solar Urticaria | |
| Trickett et al. | Managing rosacea | |
| Benoit et al. | Psoriasis from a prosthesis: unusual Koebner phenomenon in a girl with autoamputation of the leg | |
| US20140170231A1 (en) | Pain relief compositions and methods | |
| TR201815794A2 (tr) | Sedef hastaliğini tedavi̇ edi̇ci̇ bi̇tki̇sel yağ bazli 1000 ml koyu kahverengi̇ cam şi̇şede sivi sprey | |
| HK1177102A (en) | Methods of treating or preventing acute erythema | |
| Elewshi et al. | Family Practice News. 43.14 (Sept. 1, 2013): pS11. |